Objectives: Our goal was to compare the activities of lacticin 3147 and nisin, two of the most well characterized lantibiotics, against antibiotic-resistant staphylococci and enterococci. Results: Lacticin 3147 displayed potent activity against VRE with MIC values between 1.9 and 7.7 mg/L, and varying levels of activity against S. aureus strains (MRSA, 1.9 -15.4 mg/L; laboratory strains, 15.4 mg/L; hVISA, 15.4-30.9 mg/L; VISA, 61.8 mg/L). Nisin was more active against the S. aureus strains in general (MRSA and laboratory strains, 0.5 -4.1 mg/L; VISA and hVISA, 2 to 8.3 mg/L), but was less effective than lacticin 3147 against VRE (2 to 8.3 mg/L).
Introduction
Lantibiotics are ribosomally synthesized antimicrobial peptides distinguished by the presence of lanthionine and b-methyllanthionine, unusual amino acid residues formed as a result of post-translational modifications. 1 -3 A number of lantibiotics are viewed as having potential as medically significant antimicrobials, 4 especially those that function by a distinctive dual mode of action, which involves binding to lipid II, an essential intermediate in peptidoglycan biosynthesis, followed by insertion into the membrane of the target cell to form a pore. 5 Nisin A and lacticin 3147, two of the most extensively characterized lantibiotics (Figure 1 ), possess this dual mode of action. 6, 7 Nisin, like the majority of lantibiotics, is a onepeptide antimicrobial and is 34 amino acids in length. In contrast, lacticin 3147 is a two-peptide lantibiotic consisting of both Ltna (formerly LtnA1) and Ltnb (formerly LtnA2), which are 30 and 29 amino acids in length, respectively. Both antimicrobials are produced by food-grade Lactococcus lactis strains and nisin is used as a food preservative in over 48 countries worldwide. 8 However, due to the continuing emergence of multidrug-resistant pathogens, researchers have had to consider every alternative to existing antibiotic therapies. Antibiotic-resistant Staphylococcus aureus and enterococci are a particular cause for concern. Methicillin-resistant forms of S. aureus (MRSA) were first isolated in 1961 9 and have become a major problem worldwide, causing a variety of nosocomial and community-acquired infections, ranging from minor skin abscesses to life-threatening diseases such as bone and soft tissue intra-surgical infections, sepsis and invasive endocarditis. 10 -12 Until the relatively recent emergence of newer alternatives such as linezolid and daptomycin, the lipid II-targeting glycopeptide vancomycin (which binds with high affinity at the D-Ala-D-Ala portion of the lipid II pentapeptide 13 ) was regarded as the antibiotic of last resort when tackling multidrug-resistant S. aureus. However, since a strain that possessed an intermediate level of resistance to vancomycin was first observed in 1996, 14 16 which is thought to act as a physical barrier to block the access of vancomycin, and the anomalous diffusion of vancomycin through its cell wall as a result of clogging of the cell wall with vancomycin itself. 17 Staphylococci may also become partially resistant to vancomycin, a phenomenon termed 'heterogeneous VISA' or hVISA. These populations have a mixture of susceptible (MIC, 4 mg/mL) and resistant (MIC, 14 mg/mL) bacteria. 18 Although VRSA fortunately remain quite rare, vancomycin-resistant enterococci (VRE), from which the VRSA have acquired vancomycin resistance determinants, are much more common. In contrast to (h)VISAs (i.e. hVISAs and VISAs), VREs and VRSAs are resistant as a result of a conversion of the terminal D-Ala residue into a D-Lac, which reduces the efficacy of vancomycin binding. 19 Thus, although enterococci are commensal organisms that form part of the human faecal flora and were once regarded as low-grade pathogens, since the 1990s they, and VREs in particular, have become an increasingly important cause of hospital-acquired infections, including urinary tract, intra-abdominal and pelvic infections. 20 Enterococci also cause surgical wound infections, endocarditis, 10 neonatal sepsis and, rarely, meningitis and are the third most common cause of bacteraemia in the USA. 21 Evidence already exists that nisin and lacticin 3147 are active against Gram-positive clinical pathogens (for a review see Piper et al. 4 ). In addition to being active against Streptococcus pneumoniae, 22 Staphylococcus epidermidis 23, 24 and Clostridium difficile, 25, 26 nisin has also been shown to inhibit MRSA 27 -29 (MIC ranges determined to be 10-20 mg/L, 1-32 mg/L and 1.5 -16 mg/L, respectively, in three separate studies) and VRE 27, 28 (1.5 -16 mg/L and 10 -20 mg/L, respectively, in each of two studies). Lacticin 3147 is active against penicillin-resistant S. pneumoniae, Propionibacterium acnes, Streptococcus mutans 30 and C. difficile, 31 but although activity against MRSA and VRE has been demonstrated using a crude extract, 30 MICs have not been determined. 30 Neither nisin nor lacticin 3147 has been assessed with respect to anti-(h)VISA activity.
This study contains the first detailed comparison of the specific activities of the two most extensively characterized, broad-spectrum lantibiotics against clinically relevant pathogens and provides data pertaining to the specific activity of lacticin 3147 against MRSA, (h)VISA and VRE and of nisin against (h)VISA for the first time. Relative specific activities of lacticin 3147 and nisin Protection Agency (HPA), Colindale, UK. Six VISA and five hVISA strains were obtained from the Bristol Centre of Antimicrobial Research and Evaluation (BCARE), UK. Four methicillin-susceptible S. aureus (MSSA) strains were also assayed; i.e. S. aureus 113, S. aureus NCTC 8325-4, S. aureus Newman and S. aureus RF122. S. aureus strains were cultured in Mueller -Hinton broth at 378C with aeration. VRE strains were cultured in cation-adjusted Mueller -Hinton broth in accordance with the CLSI (formerly NCCLS) microbroth method 32 at 378C without aeration.
Materials and methods

Bacterial strains and culture conditions
Preparation of lantibiotics
Nisin A (hereafter nisin; 2.5% w/w; Sigma, Poole, Dorset, UK) stock solutions were prepared as described previously 27 by dissolving 0.25 g of nisin into 1 mL of 1 M HCl for 2 h at room temperature. This volume was made up to 50 mL with distilled water and the solution was then filtered through a 0.2 mm membrane. BSA was added to the solutions at 5 mg/mL to prevent the adherence of nisin to the microtitre plates. 33 Lacticin 3147 was prepared as described previously by Cotter et al. 34 An overnight culture of the lacticin 3147 overproducing strain Lactococcus lactis subsp. cremoris MG1363 ( pMRC01, p0MO2) 35 was grown in M17 medium (Oxoid) supplemented with 0.5% glucose at 308C without aeration. This was subsequently inoculated into 1 L of modified tryptone yeast broth (1% inoculum) and incubated overnight at 308C. The cells were then subsequently harvested by centrifugation at 7000 g for 20 min. The resulting pellets were re-suspended in 250 mL of 70% propan-2-ol, pH 2 (adjusted to pH 2 using concentrated HCl). After being magnetically stirred at 48C for 4 h, the cells were then removed by centrifugation. The supernatant containing the bacteriocin was reduced to a volume (60 mL) by rotary evaporation wherein the propan-2-ol was removed. The resultant preparation was then applied to a Varian C 18 Bond Elut Column (Varian, Harbor City, CA, USA) preequilibrated with methanol and water. The column was subsequently washed with 120 mL of 40% ethanol and inhibitory activity was eluted with 100 mL of 70% propan-2-ol, pH 2. The bacteriocin preparation was concentrated to a volume of 5 mL through the removal of the propan-2-ol by rotary evaporation. Aliquots of 1 mL were then applied to a phenomenex C 18 reverse phase (RP)-HPLC column (Phenomenex, Macclesfield, Cheshire, UK) previously equilibrated with 25% propan-2-ol/0.1% aqueous trifluoroacetic acid (TFA). The column was then developed in a gradient of 30% propan-2-ol containing 1% TFA to 60% propan-2-ol containing 1% TFA from 4 to 40 min at a flow rate of 1.2 mL/min. Fractions were then collected and assayed for activity against the indicator strain L. lactis HP. Each culture was assessed according to its HPLC profile and proposed fractions representing lacticin 3147 peptides Ltna and Ltnb were subjected to mass analysis with a Shimadzu Biotech MALDI-TOF Mass Spectrometer (model AXIMA-CFR plus). 34 
MIC determinations
MICs were determined in triplicate in 96-well microtitre plates (Sarstedt) as described previously. 7, 34 In brief, target strains were grown overnight in the appropriate conditions and medium, subcultured into fresh broth, allowed to grow to an OD 600 of 0.5, diluted to a final concentration of 10 5 cfu/mL in a volume of 0.2 mL and placed in the wells of the microtitre plate. Nisin and lacticin 3147 were adjusted to a 2.5 mM (or 10 mM in the case of more resistant strains) starting concentration and 2-fold serial dilutions of the peptide were added to the target strain. The MIC value was interpreted as the lowest concentration of peptide that resulted in the absence of apparent growth of the target after 16 h of incubation at 378C for all strains involved.
Enterococcus-based PCR
PCR was employed to establish the species of the VRE strains assessed and to investigate the distribution of genes encoding lacticin 3147 immunity homologues among these strains. Genomic DNA from the strains in question was extracted using a High Pure PCR Template Preparation Kit (Roche Applied Sciences) and oligonucleotides were synthesized by Eurofins MWG Operon. A PCR to discriminate between Enterococcus faecium and Enterococcus faecalis was employed as described by Dutka-Malen et al. 36 using the E. faecalis-specific primers ddl E.faecalis E 1 (5 0 -ATCAAGTACA GTTAGTCT-3 0 ) and ddl E.faecalis E 2 (5 0 -ACGATTCAAAGCTAACT G-3 0 ) and the E. faecium-specific primers ddl E.faecium F 1 (5 0 -TAGA GACATTGAATATGC-3 0 ) and ddl E.faecium F 2 (5 0
0 ) were employed to detect the presence of efdFE, i.e. homologues of the lacticin 3147 immunity genes ltnFE. The PCR was performed according to standard procedures using BioTaq DNA polymerase (Bioline) using genomic DNA extracted from VRE strains and cycled under the following conditions: 948C for 1 min, 508C for 1 min and 728C for 1 min, for 30 cycles.
Results and discussion
Despite being the two most extensively investigated lantibiotics, the antimicrobial activity of nisin and lacticin 3147 against a common set of pathogenic targets has never been directly compared. To address this issue, MIC determination assays were carried out using a selection of S. aureus, including laboratory MSSA strains (4), MRSA (20) , (h)VISA (6 VISA and 5 hVISA), and Enterococcus (VRE; 20) isolates. It should be noted that although the data are presented as mg/L values, as a consequence of being a two-peptide lantibiotic, the combined molecular weight of lacticin 3147 (6152 g/mol) is almost twice that of nisin (3488 g/mol) and thus it was deemed useful to also indicate molar values. A comparison of the activity of both lantibiotics against S. aureus strains revealed that the activity of nisin is in general superior to that of lacticin 3147 ( Table 1 ). The activity of nisin against MRSA isolates was comparable with that against the MSSA laboratory strains; i.e. MICs varied from 2 to 4.1 mg/L (625 -1250 nM; Table 1 ) for all except a few exceptionally susceptible isolates, which were inhibited by concentrations of 1 mg/L. The activity of lacticin 3147 against MRSA, with the exception of two isolates that are quite susceptible, ranged from 7.7 to 15.4 mg/L (1250 -2500 nM; Table 1) , and activity versus the four laboratory strains was surprisingly low at 15.4 mg/L (2500 nM). It was notable that in addition to possessing differing levels of activity, the lantibiotics also differed with respect to relative activity against particular strains.
Further investigations established that, in general, VISA isolates exhibited greater levels of resistance to both lantibiotics than their MRSA counterparts, in that nisin MICs increased 1.7-fold (from an average of 2.7 mg/L for MRSA to an average of 4.5 mg/L for hVISA) and lacticin 3147 MICs increased 2.2-fold (from an average of 11.45 mg/L for MRSA to an average of 24.7 mg/L for hVISA). VISA isolates were even more resistant as evidenced by, with one exception, nisin MICs of 8.3 mg/L and, in all cases, lacticin 3147 MICs of 61.8 mg/L. The enhanced resistance of (h)VISAs to the lantibiotics is not entirely unexpected given that, rather than being protected through a specific alteration to the D-Ala-D-Ala dipeptide termini of the lipid II peptidoglycan precursors, (h)VISAs are thought to be resistant as a consequence of limiting the access of vancomycin, and potentially other lipid II-binding antimicrobials, to the cell membrane. This manifests itself in the presence of thicker cell walls due to an accumulation of peptidoglycan, which greatly reduces the penetration of vancomycin through the cell wall. 16, 37 For example, the Mu50 VISA isolate was found to contain between 30 -40 layers of peptidoglycan in its cell wall, 38 whereas a vancomycin-susceptible strain of S. aureus has only 20 layers, 17 resulting in a 1.64-fold difference in cell wall thickness. 39 This in turn leads to enhanced clogging of the cell wall with the antimicrobial. 17 The fact that VISA isolates were more resistant than their hVISA counterparts was not unexpected. hVISAs are S. aureus strains that are vancomycin-susceptible by MIC testing but contain a subpopulation of cells capable of growth at higher vancomycin concentrations, whereas VISA strains contain an entire population of cells that exhibit the same level of vancomycin resistance.
In contrast to S. aureus assays, it was evident that lacticin 3147 was in general the more potent of the two lantibiotics against VRE isolates (Table 2) . With the exception of one relatively more resistant strain (MIC 7.7 mg/L; 1.25 mM), lacticin 3147 MIC values all ranged between 1.9 mg/L (312.5 nM) and 3.8 mg/L (625 nM; average¼3.1 mg/L). In contrast, nisin MICs ranged from 2 mg/L to 8.3 mg/L (or from 625 to 2500 nM; average .5.7 mg/L). The relative susceptibility of the VREs provides further evidence that alterations to the D-Ala-D-Ala dipeptide of lipid II do not provide protection against lipid II-targeting lantibiotics.
It has been noted recently that the genome sequenced strain E. faecium DO possesses efdFE, genes that are homologous to those encoding the lacticin 3147 immunity proteins LtnFE [the individual components of an ABC transporter produced by the natural lacticin 3147 producer to provide immunity (selfprotection)]. 40 Although attempts to delete the efdFE genes from an E. faecium strain with a view to determining their contribution to innate lacticin 3147 resistance were unsuccessful, it was apparent that upon heterologous expression they did provide protection against the lantibiotic. 40 Here a PCR-based strategy established that 15 of the 20 VRE used in this study were efdFEþ and, after subsequent investigations to discriminate between E. faecium and E. faecalis VREs, it became apparent that all E. faecium were efdFEþ whereas all E. faecalis were efdFE2 (Table 2) . Despite this, representatives of the two species did not, in general, differ dramatically with respect to their susceptibility to lacticin 3147 (E. faecium/efdFEþ, average MIC 3.3+1.5 mg/L; E. faecalis/ efdFE2, average MIC 2.7+1.0 mg/L). These results do not necessarily indicate that EfdFE does not contribute to the natural innate resistance of E. faecium to lacticin 3147 as E. faecalis may possess alternative protective mechanisms. However, it is apparent that if protection is provided, it is not sufficient to preclude the use of lacticin 3147 as an anti-E. faecium agent.
Although the activities of lacticin 3147 and nisin against L. lactis HP and Micrococcus flavus DSM 1790 have previously been compared, 7 this is the first instance where their activities against pathogenic strains have been investigated. It is evident from this study that both lantibiotics display reduced activity against (h)VISA isolates, presumably as a consequence of reduced access to lipid II and the cell membrane. Although both possess anti-staphylococcal and anti-enterococcal activity, it was apparent that they differ with respect to their relative potency against the various targets with nisin being more effective against S. aureus and lacticin 3147 being more effective against enterococci. Although both are thought to bind the MurNAc-PP moiety of lipid II, 6, 7, 41, 42 and thus are not negatively impacted by the alteration of the lipid II pentapeptide associated with VRE and VRSA (indeed the fusion of vancomycin with the first 12, lipid II-binding, residues of nisin enhances the activity of vancomycin against VRE), 43 differences in their mechanism of action have been noted. For example, pores formed by lacticin Relative specific activities of lacticin 3147 and nisin 3147 are much smaller in diameter (0.6 nm) 7 than those formed by nisin (2 nm). 44 Furthermore, although it has been established that nisin can induce autolysis of susceptible staphylococcal strains by causing massive cell wall degradation of the septa between dividing cells, 45 it has not yet been determined if lacticin 3147 possesses this ability. Although the basis for variations in the potency of these lantibiotics will require further investigation, the fact that variations exist highlights the merits of assessing the activities of lantibiotics against pathogenic targets to ensure that those with the greatest potential for specific applications are identified. The existence of variations also indicates that there may be merit in using these lantibiotics in combination. This will form the basis of future studies.
In conclusion, the data presented here suggest that the continued research of existing lantibiotics such as nisin and lacticin 3147, possibly coupled with the further isolation of novel natural lantibiotics or even bio-engineered derivatives, 46 -48 could result in the ultimate development of such compounds as antimicrobials for clinical use. 
